Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment